leadf
logo-loader
viewTissue Regenix Group PLC

Tissue Regenix's production capacity increases should bear fruit in the second half

During the first half, the regenerative medicines specialist streamlined its logistics network and enhanced its operational procedures

Tissue Regenix Group PLC -
Operationally, the firm has begun a second shift for its BioRinse products, while improvements to the supply chain continued to deliver “efficiencies”

Tissue Regenix Group PLC (LON:TRX) said it was focused on initiatives to increase capacity and alleviate supply “constraints” as it continued to see strong demand for its products.

During the first half, the regenerative medicines specialist streamlined its logistics network and enhanced its operational procedures, said chairman John Samuel, commenting on the company’s first-half results.

“These initiatives have enabled us to increase production capabilities within the San Antonio facility, the benefits of which will come to fruition in the second half of the year,” he added.

Tissue Regenix’s financial performance is likely to be second-half weighted as the aforementioned initiatives increase overall capacity, the company re-confirmed.

Still, it made a solid start as its sales rose £500,000 to £6.1mln during the six months ended June 30, boosted by revenues from its DermaPure skin repair product, which grew by 33% to £2mln.

Expansion plans are being backed by a £16.2mln (US$20mln) credit facility from MidCap Financial. At the end of the period the firm’s cash balance was £10.1mln following a £6.1mln drawdown from MidCap.

In common with companies at this formative stage of commercial development, Tissue Regenix was loss-making in the first half – to the tune of £3.6mln at the EBITDA level. That was broadly in line with the deficit this time last year.

Commercially, the group accelerated “US market penetration” in the early part of the year, while expanding the group purchasing coverage for DermaPure.

Operationally, it has begun a second shift for its BioRinse products, while improvements to the supply chain continued to deliver “efficiencies”.

Quick facts: Tissue Regenix Group PLC

Price: 0.332 GBX

AIM:TRX
Market: AIM
Market Cap: £23.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: FTSE 100 heads higher as markets welcome easing of restrictions

Headlines from the Proactive UK newsroom. The FTSE 100 rose 21 points to 6,957 as markets welcomed more easing of coronavirus lockdown measures across Europe despite some confusion in the UK. UK prime minister Boris Johnson, though, is being pressed for more clarity on the relaxation of UK...

on 11/5/20

2 min read